drugset / Trial / NCT04277845
Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the efficacy and safety of bortezomib, lenalidomide and dexamethasone in elderly frail patients with newly diagnosed multiple myeloma.
Timeline
- Start
- 2020-08-06
- Primary completion
- 2022-03-23
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1 mg/m2 | Subcutaneous |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Background | Dexamethasone | Small molecule | 20 mg | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |
| Background | Lenalidomide | Other / unclassified | 15 mg | — |
| Background | Lenalidomide | Other / unclassified | 25 mg | — |